Esperion Therapeutics Inc. (NASDAQ: ESPR) is -40.47% lower on its value in year-to-date trading and has touched a low of $0.70 and a high of $3.40 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ESPR stock was last observed hovering at around $1.90 in the last trading session, with the day’s loss setting it -0.12%.
Currently trading at $1.78, the stock is -15.68% and -24.26% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.81 million and changing -6.32% at the moment leaves the stock -18.79% off its SMA200. ESPR registered 22.76% gain for a year compared to 6-month loss of -33.58%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -26.14% gain in the last 1 month and extending the period to 3 months gives it a -28.23%, and is -1.11% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.39% over the week and 7.38% over the month.
Esperion Therapeutics Inc. (ESPR) has around 240 employees, a market worth around $337.24M and $277.79M in sales. Fwd P/E is 8.75. Profit margin for the company is -35.46%. Distance from 52-week low is 154.29% and -47.65% from its 52-week high. The company has generated returns on investments over the last 12 months (-55.65%).
with sales reaching $53.85M over the same period.The EPS is expected to grow by 88.18% this year, but quarterly earnings will post 201.10% year-over-year.
Esperion Therapeutics Inc. (ESPR) Top Institutional Holders
207.0 institutions hold shares in Esperion Therapeutics Inc. (ESPR), with institutional investors hold 70.86% of the company’s shares. The shares outstanding are 189.46M, and float is at 187.38M with Short Float at 20.35%. Institutions hold 70.51% of the Float.
The top institutional shareholder in the company is ORBIMED ADVISORS LLC with over 13.71 million shares valued at $36.74 million. The investor’s holdings represent 12.196 of the ESPR Shares outstanding. As of 2024-03-31, the second largest holder is BELLEVUE GROUP AG with 9.94 million shares valued at $26.65 million to account for 8.8468 of the shares outstanding. The other top investors are WASATCH ADVISORS LP which holds 9.13 million shares representing 8.1222 and valued at over $24.47 million, while VANGUARD GROUP INC holds 7.8526 of the shares totaling 8.83 million with a market value of $23.66 million.
Esperion Therapeutics Inc. (ESPR) Insider Activity
The most recent transaction is an insider sale by Warren Eric, the company’s Chief Commercial Officer. SEC filings show that Warren Eric sold 211 shares of the company’s common stock on Aug 19 ’24 at a price of $1.95 per share for a total of $411.0. Following the sale, the insider now owns 0.17 million shares.
Still, SEC filings show that on Jul 17 ’24, Warren Eric (Chief Commercial Officer) disposed off 108 shares at an average price of $2.59 for $279.0. The insider now directly holds 165,478 shares of Esperion Therapeutics Inc. (ESPR).
